Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Alzheimer’s Disease Diagnostic Market Growth Performance Trended Historically, And What Lies Ahead?
The market size for diagnosing Alzheimer’s disease has experienced a significant growth in recent past. It is expected to increase from a value of $6.56 billion in 2024 to $7.26 billion in 2025 with a compound annual growth rate (CAGR) of 10.7%. Factors contributing to this growth in the historic period include the rising incidence of Alzheimer’s disease and dementia, increased awareness about the significance of early diagnosis for improved management, advancements in imaging technologies such as MRI and PET scans, as well as rising investments in research and development focused on neurodegenerative diseases. Additionally, governmental initiatives and funding dedicated towards Alzheimer’s research and diagnostics have also played a role in this expansion.
In the coming years, a swift expansion is forecasted for the Alzheimer’s disease diagnostic market, with an estimation to reach $10.81 billion by 2029 with a 10.5% compound annual growth rate (CAGR). This upward trend during the forecasted period is due to the advancements in non-invasive diagnosis with blood-based biomarkers, increasing requirement for personalized medicine and precision diagnostics, integration of Artificial Intelligence and machine learning into diagnostic tools for preemptive detection, the rising adoption of digital health technologies for remote monitoring and diagnosis, as well as the developing healthcare infrastructure in emerging markets to enhance accessibility. There is an emerging trend in the forecast period of multi-modal diagnostic procedures that merge imaging, biomarkers and cognitive tests, a growing emphasis on swift results through point-of-care diagnostic solutions, development of wearable devices enabling continuous cognitive-health monitoring, greater collaborations between biotech firms and research institutions for innovative solutions, and an increase in direct-to-consumer genetic testing for Alzheimer’s risk determination.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp
What Are the Core Growth Drivers Propelling the Alzheimer’s Disease Diagnostic Market Forward?
The surge in chronic illnesses is anticipated to fuel the expansion of the Alzheimer’s disease diagnostic market in the future. Chronic diseases, which are health conditions that persist or last longer than three months, have seen an uptick due to a combination of various interconnected factors. These include lifestyle decisions, environmental factors, genetic predisposition, and socioeconomic conditions. Chronic conditions such as cardiovascular issues, diabetes, and hypertension heighten the risk of developing Alzheimer’s disease (AD) and other types of dementia. For example, a January 2022 report from the American Heart Association Inc., a nonprofit volunteer organization based in the U.S., predicts that brain disorders will rise to 9.3 million by 2060 in the U.S., and this figure is currently increasing. Moreover, one out of six people globally suffers from a brain disorder. It is projected that by 2021, 1 billion people worldwide will be affected by brain disorders. Consequently, the rise in chronic illnesses will fuel the expansion of the Alzheimer’s disease diagnostic market.
What Segment Types Define the Alzheimer’s Disease Diagnostic Market Structure?
The alzheimer’s disease diagnosticmarket covered in this report is segmented –
1) By Type: Triage; Diagnosis; Screening
2) By Diagnostic Technique: Biomarkers; Imaging Techniques; Genetic Testing; Cognitive Assessment Tests
3) By End User: Clinics; Hospitals; Diagnostic Centers; Pharmaceutical Companies; Academic Research Center
Subsegments:
1) By Triage: Cognitive Testing; Imaging Techniques
2) By Diagnosis: Biomarker Testing; Neuroimaging
3) By Screening: Neuropsychological Testing; Genetic Testing
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21093&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Alzheimer’s Disease Diagnostic Market?
North America was the largest region in the alzheimer’s disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Emerging Trends that Are Influencing theAlzheimer’s Disease Diagnostic Industry Evolution?
Key organizations in the Alzheimer’s disease diagnostic market are concentrating on the development of blood-based biomarker tests, a strategy anticipated to streamline the diagnostic process for Alzheimer’s, reduce dependence on more invasive methods, and enhance the availability of timely treatments for patients. For example, Quanterix, a biotechnology research firm based in the US, introduced the LucentAD p-Tau 217 test in October 2023. It serves as a biomarker presenting clinical sensitivity and specificity in blood for Alzheimer’s pathology. Classic procedures for cerebrospinal fluid (CSF) biomarkers encompass positron emission tomography (PET), or lumbar puncture, all of which prove expensive, invasive, and not easily accessible. Moreover, it synergizes Quanterix’s extremely sensitive SimoaÒ technology with p-Tau 217 antibodies tested and approved by J&J Innovative Medicine to promise excellent precision and a simplified procedure.
View the full report here:
https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report
What Is the Definition of the Alzheimer’s Disease Diagnostic Market?
Alzheimer’s disease diagnostics encompass methods and tools used to detect and confirm the presence of Alzheimer’s disease, a progressive neurodegenerative disorder. These diagnostics include cognitive assessments, imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, and biomarker tests analyzing cerebrospinal fluid (CSF) or blood for amyloid-beta and tau proteins.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21093
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model